1. Chinese innovative drugs are gaining popularity overseas, with both independent expansion and partnerships driving growth.

Chinese Innovation in Pharmaceuticals: The Drive to Go GlobalThe enthusiasm for Chinese innovative drugs going global continues to rise, with pharmaceutical companies actively exploring international markets through two models: independent expansion and partnerships. In 2023, both the number of overseas deals and drug approvals for Chinese innovative medicines reached record highs, showcasing the innovation capabilities and global strides of Chinese pharmaceutical companies. Enhancing medical standards and nurturing top-tier healthcare professionals are crucial to supporting the globalization of China's pharmaceutical innovations.

2. China's First "Recombinant Type III Collagen Hyaluronic Acid Injection" Officially Goes to "SkinCeuticals"

Jinbo Biotech Collaborates with SkinCeuticals to Launch China’s First Recombinant Type III Collagen Hyaluronic Acid Injection "Platinum Research" Collagen Needle for Facial Wrinkle Correction

3. China's Self-Developed Endoscopic Surgical Robot "Gold Standard" Debuts: Nanchang University First Affiliated Hospital Completes Robot-Assisted Radical Prostatectomy

The First Affiliated Hospital of Nanchang University successfully completed a robot-assisted radical prostatectomy using the TRLing® Endoscopic Surgical Robot developed by Todor Medical. This marked the "gold standard" debut of the robot in the industry, showcasing its advantages in precise dissection, stable performance, and smooth operation, earning high praise from medical staff. The surgery is a milestone, highlighting Todor Medical's technological innovation capabilities and leading position in the surgical robotics field.

4. Boehringer Ingelheim partners with Shanghai RAAS to develop innovative hemophilia drugs

Boehringer Ingelheim Collaborates with Shanghai RAAS to Develop SR604 Injection, an Innovative Hemophilia Drug; Boehringer Ingelheim to Provide Technology Transfer and Clinical Manufacturing Services for the Drug. SR604 Injection Expected to Offer a New Treatment Option for Hemophilia Patients. The Partnership Aims to Advance R&D and Production of Innovative Drugs in China, Benefiting Patients Worldwide.

5. Johnson & Johnson's Dual Antibody Challenge to the Third-Generation EGFR-TKI Resistance Stalemate

Johnson & Johnson's Rybrevant Receives FDA Approval, Combined with Chemotherapy as First-Line Treatment for EGFR Exon 20 Insertion Mutation in NSCLC. The EGFR-TKI Market is Broad but Still Has Unmet Clinical Needs. Third-Generation EGFR-TKIs Become the Main Force in the Market, Led by Osimertinib, with Intense Competition Among Multiple Drugs Produced in China.